PolyPeptide soars after wins 100-million-euro annual deal
** PolyPeptide PPGN.S shares skyrocket around 15% after
the Swiss group said it has signed a deal worth around 100
million euros ($106.36 million) annually starting in 2024
** The firm, which makes peptides for pharma and biotech
companies, said the deal was for one of its phase III custom
projects
** PolyPeptide's shares top Switzerland's midcaps index
.SMII in Julius Baer pre-market trade
($1 = 0.9402 euros)
(Reporting by Tristan Chabba)
((Tristan.chabba@thomsonreuters.com))
Recent news on PolyPeptide AG
See all newsBrief: Polypeptide Group Definitive Interim Result Of The Public Tender Offer Of Samsung Biologics
Brief: Polypeptide Group Provisional Interim Result Of The Public Tender Offer Of Samsung Biologics Co
Deals of the day-Mergers and acquisitions
Deals of the day-Mergers and acquisitions
Samsung Biologics to launch takeover bid for PolyPeptide in September (updated)